湿疹方微乳凝胶制备及其质量评价的研究
|
摘要
湿疹为临床常见病,多发病,是由机体内外激发因子引起的一种迟发型变态反应,并伴随激烈瘙痒或皮肤炎症现象。西药多采用激素、抗生素或抗组胺类药物治疗该病,长期使用,毒副作用大,临床使用受限。湿疹方是治疗湿疹的临床验方,由黄连、苦参、牡丹皮及冰片等4味中药组成,具有清热解毒、燥湿止痒、调节机体免疫的功效,该方临床以洗剂外用,疗效确切,但存在药效成分不明确,提取制备方法原始、粗简,缺乏标准,内在质量难以控制,载药量小,作用时间短,生物利用率低等缺点,同时洗剂使用和携带均不方便,影响了其临床推广应用。为了提升该方质量稳定性,增强药效成分的透皮性能,提高疗效及患者的使用依从性,在前期洗剂的研究基础上,本课题对湿症方进行了系统研究,取得了较满意的结果。
本文首先通过湿疹方提取、纯化工艺路线的研究,确定了湿疹方的最佳提取纯化工艺路线,优化了处方中各中药的提取、纯化工艺,通过处方前研究掌握了各纯化物的理化性质,综合应用微乳与凝胶制备技术,将湿疹方纯化物药物,制备成了复方湿疹微乳凝胶剂,并对其进行质量评价。全文主要研究内容如下：
1湿疹方提取纯化工艺路线的确定
针对本制剂制备的需要,分别采用药效学方法,以小鼠接触性湿疹模型中耳肿胀抑制率为评价指标,探讨本品处方中药材分煎、合煎以及不同提取组分物对药效的影响。结果表明,与模型对照组比较,单煎组与合煎组对小鼠接触性湿疹均有明显的抑制作用(P<0.01),且两组之间无明显差别(P>0.05),提示,处方中药材可采用单独提取,所得提取纯化物加入处方量冰片制备成制剂；采用正交试验法,以小鼠接触性湿疹中耳肿胀抑制率为考察指标,考擦本品处方量黄连、苦参、牡丹皮不同提取纯化物与冰片混合后的药效,结果表明,黄连总生物碱纯化物、苦参总生物碱纯化物、丹皮酚、冰片混合物作用最好,初步确定处方各中药提取纯化工艺路线,为湿疹方各中药的提取方法和后续的处方工艺研究奠定了基础。
2提取纯化工艺的优化
(1)指标成分的含量测定：采用HPLC法分别对黄连总生物碱纯化物指标成分“HLJ”(盐酸小檗碱、巴马汀、黄连碱及表小檗碱总和)、苦参总生物碱纯化物指标成分“K”(苦参碱与氧化苦参碱总和)及丹皮酚进行了含量测定,建立的方法灵敏准确,简单实用,为本课题的研究提供了可靠的检测手段。(2)黄连提取纯化工艺优化：以HLJ的转移率为考察指标,优选黄连提取纯化工艺。采用单因素与正交试验结合法,确定黄连提取工艺为：取黄连药材饮片,加8倍量1.5%(m/m)硫酸溶液回流提取3次,每次40分钟,HLJ提取率高达93%；提取液以酸碱置换及盐析相结合的方法,制得黄连总生物碱纯化物,总碱含量(以HLJ计)大于80%,得率7.70%,方法工艺稳定,可行。(3)苦参提取纯化工艺优化：以K的转移率为考察指标,优选苦参提取纯化工艺。采用单因素试验结合星点设计.效应面法,确定苦参提取工艺为：取苦参药材饮片,加11倍量65%的乙醇提取2次,每次65分钟,K提取率大于90%,总固物得率大于23%；提取液过732型阳离子树脂柱,制得苦参总生物碱纯化物,总碱含量(以K计)大于41%,得率4.67%,方法工艺稳定,可行。(4)牡丹皮提取纯化工艺优化：采用水蒸气蒸馏法,以丹皮酚收率为考察指标,确定丹皮酚制备工艺为：取牡丹皮药材饮片,加8倍量水,浸泡2小时,共水蒸馏,收集药材5倍量馏出液；馏出液冷藏,取沉淀,制得丹皮酚,丹皮酚含量大于96%,得率1.11%,方法工艺稳定,可行。
3处方前研究
对黄连总生物碱纯化物、苦参总生物碱纯化物、丹皮酚制剂处方设计前的主要理化性质进行了测试。结果表明,HLJ微溶于水,K易溶于水,其油水分配系数均小于1,其中,K的油水分配系数大于HLJ,丹皮酚易溶于有机溶剂,油水分配系数较大；稳定性试验结果表明,黄连总生物碱纯化物、苦参总生物碱纯化物对光、湿、热稳定,丹皮酚易升华挥发；以黄连总生物碱指标成分HLJ以及丹皮酚为考察指标,对湿疹方的体外透皮性能进行了考察,结果表明,黄连总生物碱中HLJ透皮速率为6.36ug.cm-2.h-1,丹皮酚透皮速率为6.83ug.cm-2.h-1,吸收机制均符合为零级过程。以上工作为剂型的选择和制备工艺的确定提供了依据。
4复方湿疹微乳凝胶制备工艺研究
为提高药物的透皮性能,采用微乳作为药物载体,结合凝胶剂的特点,制备复方湿疹微乳凝胶。在复方湿疹微乳制备研究中,通过单因素及正交试验筛选出微乳的油相、表面活性剂、助表面活性剂、水相分别为：肉豆蔻酸异丙酯(IPM)、Cremephor EL(EL)、丙三醇、去离子水；通过体外透皮试验,以药物透皮性能为考察指标,确定微乳各相的百分含量,筛选出最佳微乳处方为：IPM6.5%,EL-丙三醇(1：1)58.5%,水35%,所制得的复方湿疹微乳药物透皮效果最佳。
对空白微乳理化性质进行了考察,结果显示微乳粒径分布范围10-100nm, Zeta电位为负。微乳对提取纯化物具有增溶性,对试验内的药物、温度、pH值均具有较好的稳定性。
以复方湿疹微乳凝胶样品的光泽性、粘稠度、均匀度、涂展性、稳定性为考察指标,筛选出凝胶基质为卡波姆940(CP-940),用量为0.5%,结果表明微乳加入凝胶基质CP-940制成微乳凝胶后,体系的电势能提高,稳定性增强。透射电镜观察呈圆球形,粒径在100nm内。验证试验显示,复方湿疹微乳凝胶制备工艺稳定、可行。
5复方湿疹微乳凝胶质量评价
生物学评价：通过量效关系的考察确定复方湿疹微乳凝胶的载药量为0.9%,其中黄连总生物碱纯化物含量为0.47%,其余各提取纯化物折算为原处方生药比例加入。小鼠实验性湿疹试验中,相同生药载药量的原湿疹方洗剂与复方湿疹微乳凝胶剂比较,后者较前者药效得到显著提高(P<0.01)。安全性考察试验,结果显示复方湿疹微乳凝胶制剂无不良刺激、无过敏性、无急性毒副作用,复方湿疹微乳凝胶药效强、安全性好。
理化评价：对复方湿疹微乳凝胶体理化常数进行评价,分别建立了TLC定性鉴别及HPLC定量分析的方法,方法准确、稳定、简便。通过透射电镜观察微乳呈圆球形,粒径小于100nm；体外透皮试验显示,复方湿疹微乳凝胶较原湿疹方洗剂药物的透皮性能显著提升(P<0.01),其中黄连总生物碱指标成分HLJ透皮速率提高了约16倍,丹皮酚透皮速率提高了约10倍；初步稳定性试验显示,复方湿疹微乳凝胶稳定性良好。
本文研制的复方湿疹微乳凝胶制剂,较原湿疹方洗剂,药物透皮性能得到显著提升,药效增强,产品药效成分明确,质量均一、稳定、可控,提高了用药的方便性、舒适性、安全性,具有良好的市场应用前景。
Eczema is a common, frequently-occurring disease, it is a kind of delayed allergic reaction, caused by evocators both from outside and inside, accompanying with intense itching or skin inflammation. Western medicine such as hormones, antibiotics, or anti-histamine, is used for curing this disease. But its clinical application is limited in this area, because of side effects for long-term use. Shi-zhen Prescription is used for curing eczema, composed of coptidis rhizoma, sophora flavescens, paeonia suffruticosa and borneol, with effects of removing pathological heat and removing toxicity, relieving itching by eliminating dampness and regulating the body's immune systerm. The prescription in form of lotion is commonly applied in clinic with its exact accurative effect. Meanwhile, its shortcomings such as uncertain pharmacodynamic materials, crude preparation with low standards, quality control difficulties, small drug loading, short action time, low bioavailability, inconvenient application and taking along, and so on, limited its clinical generalization. In order to promote the prescription quality stability, enhance the ability of drug's skin penetration, enhance the curative effect and patient compliance, systematic research was made on Shi-zhen prescription, on the basis of former studies.
In this paper, firstly, the optimal extraction and purification processes were determined by the research on extraction and purification of Shi-zhen prescription. Secondly, the physicochemical properties of the purified materials were mastered by the preformulation studies, thirdly, with integrated application of microemulsion and gel's advantage, the purified materials were made into "Shi-Zhen compound microemulsion-based gels", finally, physicochemical and biology evaluation of the new preparation was made.The main content of the research in this paper was as follows.
1Determination of the extraction and purification processes of Shi-zhen prescription
For the preparation of microemulsion-based gels, with the pharmacodynamics methodology, taking the inhibition rate of mice ears-swelling as the investigation factor, studies on the different influence on prescription's efficacy by decocting separately and together.The result showed as follows:Both single-decoction and mixed-decoction group had a significant effect on inhibiting mice ears-swell ing (P<0.01), compared with the model group, with no significant difference between single-decoction and mixed-decoction group (P>0.05). The result showed that the Shi-zhen prescription could be decocted Separately.the preparation could be made of the purified material and borneol.Taking the inhibition ratio of mice ears-swelling during the mice contact eczema test as the investigation index,studies on the coptidis rhizomas'、sophora flavescens'and paeonia suffruticosa's different extracted and purified materials's effection on the prescription's efficacy by orthogonal experimental design.The result showed that the combination of the purified matetials of total alkaloids from coptidis rhizome, total alkaloids from sophora flavescens, paeonol and borneol had the strongest efficacy. The extraction and purification processes were determined preliminarily. The above findings laid the foundation for the subsequent studies on formulation and processes.
2Optimization of the extraction and purification processes
(1) Determination of ingredient index's content:Studies on content' determination of HLJ(berberine hydrochloride, palmatine, coptisine and epiberberine), K(matrine and oxymatrine)and paeonol, which respectively stand for ingredient index of the purified materials:total alkaloids from coptidis rhizome, total alkaloids from sophora flavescens and crystals from moutan cortex. The established methods for content's determination were sensitive, accurate, simple and practical.(2) Optimization of coptidis rhizome-extraction and purification processes.Taking transfer rate of HLJ as evaluation index,the optimized extraction processes of coptidis rhizome were screened by single factor and orthogonal experimental design. The optimum condition of extraction processes were that the tablets ready for decoction were decocted with8-fold1.5%(m/m) sulfuric acid solution for3times,40min each time. The transfer rate of HLJ was above to93%;Total alkaloids was made from extract by methords of acid-base replacement and salting out method. The yield of total alkaloids was about7.70%, and the content of HLJ was more than80%. The processes of preparation were stability and feasible.(3) Optimization of sophora flavescens-extraction and purification processes:Taking transfer rate of K as evaluation index, the optimized extraction processes of sophora flavescens were screened by single factor and central composite design-response surface experimental design. The optimum condition of extraction processes were that the tablets ready for decoction were decocted with11-fold65%alcohol for2times,65min each time. The transfer rate of K was more than90%. The yield of dried extractum was more than23%. The total alkaloids was purified by732cationic resin processes,the content of which was over41%(based on the calculation of K),and the yield of which was about4.67%. The processes of preparation were stability and feasible.(4) Optimization of paeonia suffruticosa-extraction and purification processes: Taking yield of paeonol as evaluation index, The paeonol was extracted from paeonia suffruticosa by steam distillation technology, and the optimal extraction processes were as follows:the tablets ready for decoction were socked for2h, then decocted with8-fold water.5times crude drug-amuout of distillate was collected. the distillate was placed in refrigerator (4℃) for12h, Filtered, and paeonol was gotten, The yield of paeonol was aboutl.11%, and the content of paeonol was about96%。 The processes of preparation were stability and feasible.
3Preformulation studies
The studies on physicochemical properties of the purified matetials of total alkaloids from coptidis rhizome, total alkaloids from sophora flavescens and paeonol showed that HLJ was slightly soluble in water, k was hydrophilic, their oil and water distribution coefficient were both less than1, and k had larger distribution coefficient. In addition, the paenol was soluble in organic solvents, its oil and water distribution coefficient was larger than the former. Stability test results showed that the total alkaloids from coptidis rhizome and the total alkaloids from sophora flavescens were kept unchanged in the condition of light, wet, and heat, but the paenol was easily volatile. We took HLJ and paenol as the index to explore the purified materials' skin permeation. The result showed that the speed of HLJ's skin permeation was6.36ug·cm-2·h-1and the speed of paenol's skin permeation was6.83ug·cm-2·h-1. Their absorption mechanisms belonged to the zero-order kinetics. All of the above provided the basis for the forms of the choice and the determination of the preparation technology.
4Preparation of Shi-zhen compound microemulsion-based gels
In order to improve drug' ability of skin permeation, microemulsion was used as the drug delivery system.Shi-zhen compound microemulsion-based gels was prepared, combined with the characteristics of microemulsion and gels.In the research of Shi-zhen compound microemulsion-based gels' spreparation, types of oil phase, surfactant, cosurfactant were choosed by single factor and orthogonal experimental design. According to the result, isopropyl myristate (IPM, oil phase), Cremephor EL(EL, surfactant) and glycerol (cosurfactant), and double-distilled water were determined as the composition of the Shi-zhen microemulsion. Percentage composition of microemulsion's each phase was determined by in vitro transdermal permeation experiment. According to the result of the experiment,6.5%isopropyl myristate(IPM),35%double-distilled water and58.5%Cremephor EL/glycerol(1:1) as the optimal prescription of microemulsion was ascertained. The result showed the optimal microemulsion had the best ability of skin permeation.
Studies on physicochemical properties, solubilization and stability of blank micromulsion were investigated primitively. It showed that the microemulsion preparation can increase the purified materials' solubility and the stability to the purified materials, pH, and temperature in the test. Taking the glossiness, viscosity, degree of homogeneity, stretchability of the preparation as the investigation index, carbomer940was chosed as the optimal gels' base material, and the content of it was0.5%. microemulsion-based gels' zetea potential got higher than blank microemulsion, and The new preparation microemulsion-based gels got more stable than blank microemulsion,with diameter less than100nm, showing round shape in the horizon of transmission electron microscope(TEM). Verifying test showed that the processes of preparation for Shi-zhen compound microemulsion-based gels were stability, reasonable and feasible.
5Quality evaluation of the Shi-zhen compound microemulsion-based gels
Biological evaluation:Drug loading of Shi-zhen compound microemulsion-based gels was determered by the dose-effect relationship experiment, which was0.90%(calculated by the amount of the purified materials, the content of HLJ was0.47%). With the same drug loading, Shi-zhen compound microemulsion-based gels'drug efficacy was improved significantly, compared with the original lotion preparation. The Shi-zhen compound microemulsion-based gels had no side effects of irritation, irritability or acute toxicity to the guinea pigs and New Zealand rabbits.
Physicochemical evaluation:Methods of qualitative identification (TLC),and quantitative analysis(HPLC) for microemulsion-based gels were established, which were accurate, stable and reliable. According to the in vitro transdermal permeation experiment, it showed that the component HLJ's skin penetration was improved about16times, and paeonol's was improved about10times than the original lotion preparation. Preliminary stability test showed that Shi-zhen compound microemulsion-based gels had good stability.
Drugs in the Shi-zhen compound microemulsion-based gels had a higher ability of skin permeation and stronger drug efficacy.compared with the orginal lotion, the Shi-zhen compound microemulsion-based gels performed controllable, homogeneous and stable quality, convenient application and good market prospect.
本文首先通过湿疹方提取、纯化工艺路线的研究,确定了湿疹方的最佳提取纯化工艺路线,优化了处方中各中药的提取、纯化工艺,通过处方前研究掌握了各纯化物的理化性质,综合应用微乳与凝胶制备技术,将湿疹方纯化物药物,制备成了复方湿疹微乳凝胶剂,并对其进行质量评价。全文主要研究内容如下：
1湿疹方提取纯化工艺路线的确定
针对本制剂制备的需要,分别采用药效学方法,以小鼠接触性湿疹模型中耳肿胀抑制率为评价指标,探讨本品处方中药材分煎、合煎以及不同提取组分物对药效的影响。结果表明,与模型对照组比较,单煎组与合煎组对小鼠接触性湿疹均有明显的抑制作用(P<0.01),且两组之间无明显差别(P>0.05),提示,处方中药材可采用单独提取,所得提取纯化物加入处方量冰片制备成制剂；采用正交试验法,以小鼠接触性湿疹中耳肿胀抑制率为考察指标,考擦本品处方量黄连、苦参、牡丹皮不同提取纯化物与冰片混合后的药效,结果表明,黄连总生物碱纯化物、苦参总生物碱纯化物、丹皮酚、冰片混合物作用最好,初步确定处方各中药提取纯化工艺路线,为湿疹方各中药的提取方法和后续的处方工艺研究奠定了基础。
2提取纯化工艺的优化
(1)指标成分的含量测定：采用HPLC法分别对黄连总生物碱纯化物指标成分“HLJ”(盐酸小檗碱、巴马汀、黄连碱及表小檗碱总和)、苦参总生物碱纯化物指标成分“K”(苦参碱与氧化苦参碱总和)及丹皮酚进行了含量测定,建立的方法灵敏准确,简单实用,为本课题的研究提供了可靠的检测手段。(2)黄连提取纯化工艺优化：以HLJ的转移率为考察指标,优选黄连提取纯化工艺。采用单因素与正交试验结合法,确定黄连提取工艺为：取黄连药材饮片,加8倍量1.5%(m/m)硫酸溶液回流提取3次,每次40分钟,HLJ提取率高达93%；提取液以酸碱置换及盐析相结合的方法,制得黄连总生物碱纯化物,总碱含量(以HLJ计)大于80%,得率7.70%,方法工艺稳定,可行。(3)苦参提取纯化工艺优化：以K的转移率为考察指标,优选苦参提取纯化工艺。采用单因素试验结合星点设计.效应面法,确定苦参提取工艺为：取苦参药材饮片,加11倍量65%的乙醇提取2次,每次65分钟,K提取率大于90%,总固物得率大于23%；提取液过732型阳离子树脂柱,制得苦参总生物碱纯化物,总碱含量(以K计)大于41%,得率4.67%,方法工艺稳定,可行。(4)牡丹皮提取纯化工艺优化：采用水蒸气蒸馏法,以丹皮酚收率为考察指标,确定丹皮酚制备工艺为：取牡丹皮药材饮片,加8倍量水,浸泡2小时,共水蒸馏,收集药材5倍量馏出液；馏出液冷藏,取沉淀,制得丹皮酚,丹皮酚含量大于96%,得率1.11%,方法工艺稳定,可行。
3处方前研究
对黄连总生物碱纯化物、苦参总生物碱纯化物、丹皮酚制剂处方设计前的主要理化性质进行了测试。结果表明,HLJ微溶于水,K易溶于水,其油水分配系数均小于1,其中,K的油水分配系数大于HLJ,丹皮酚易溶于有机溶剂,油水分配系数较大；稳定性试验结果表明,黄连总生物碱纯化物、苦参总生物碱纯化物对光、湿、热稳定,丹皮酚易升华挥发；以黄连总生物碱指标成分HLJ以及丹皮酚为考察指标,对湿疹方的体外透皮性能进行了考察,结果表明,黄连总生物碱中HLJ透皮速率为6.36ug.cm-2.h-1,丹皮酚透皮速率为6.83ug.cm-2.h-1,吸收机制均符合为零级过程。以上工作为剂型的选择和制备工艺的确定提供了依据。
4复方湿疹微乳凝胶制备工艺研究
为提高药物的透皮性能,采用微乳作为药物载体,结合凝胶剂的特点,制备复方湿疹微乳凝胶。在复方湿疹微乳制备研究中,通过单因素及正交试验筛选出微乳的油相、表面活性剂、助表面活性剂、水相分别为：肉豆蔻酸异丙酯(IPM)、Cremephor EL(EL)、丙三醇、去离子水；通过体外透皮试验,以药物透皮性能为考察指标,确定微乳各相的百分含量,筛选出最佳微乳处方为：IPM6.5%,EL-丙三醇(1：1)58.5%,水35%,所制得的复方湿疹微乳药物透皮效果最佳。
对空白微乳理化性质进行了考察,结果显示微乳粒径分布范围10-100nm, Zeta电位为负。微乳对提取纯化物具有增溶性,对试验内的药物、温度、pH值均具有较好的稳定性。
以复方湿疹微乳凝胶样品的光泽性、粘稠度、均匀度、涂展性、稳定性为考察指标,筛选出凝胶基质为卡波姆940(CP-940),用量为0.5%,结果表明微乳加入凝胶基质CP-940制成微乳凝胶后,体系的电势能提高,稳定性增强。透射电镜观察呈圆球形,粒径在100nm内。验证试验显示,复方湿疹微乳凝胶制备工艺稳定、可行。
5复方湿疹微乳凝胶质量评价
生物学评价：通过量效关系的考察确定复方湿疹微乳凝胶的载药量为0.9%,其中黄连总生物碱纯化物含量为0.47%,其余各提取纯化物折算为原处方生药比例加入。小鼠实验性湿疹试验中,相同生药载药量的原湿疹方洗剂与复方湿疹微乳凝胶剂比较,后者较前者药效得到显著提高(P<0.01)。安全性考察试验,结果显示复方湿疹微乳凝胶制剂无不良刺激、无过敏性、无急性毒副作用,复方湿疹微乳凝胶药效强、安全性好。
理化评价：对复方湿疹微乳凝胶体理化常数进行评价,分别建立了TLC定性鉴别及HPLC定量分析的方法,方法准确、稳定、简便。通过透射电镜观察微乳呈圆球形,粒径小于100nm；体外透皮试验显示,复方湿疹微乳凝胶较原湿疹方洗剂药物的透皮性能显著提升(P<0.01),其中黄连总生物碱指标成分HLJ透皮速率提高了约16倍,丹皮酚透皮速率提高了约10倍；初步稳定性试验显示,复方湿疹微乳凝胶稳定性良好。
本文研制的复方湿疹微乳凝胶制剂,较原湿疹方洗剂,药物透皮性能得到显著提升,药效增强,产品药效成分明确,质量均一、稳定、可控,提高了用药的方便性、舒适性、安全性,具有良好的市场应用前景。
Eczema is a common, frequently-occurring disease, it is a kind of delayed allergic reaction, caused by evocators both from outside and inside, accompanying with intense itching or skin inflammation. Western medicine such as hormones, antibiotics, or anti-histamine, is used for curing this disease. But its clinical application is limited in this area, because of side effects for long-term use. Shi-zhen Prescription is used for curing eczema, composed of coptidis rhizoma, sophora flavescens, paeonia suffruticosa and borneol, with effects of removing pathological heat and removing toxicity, relieving itching by eliminating dampness and regulating the body's immune systerm. The prescription in form of lotion is commonly applied in clinic with its exact accurative effect. Meanwhile, its shortcomings such as uncertain pharmacodynamic materials, crude preparation with low standards, quality control difficulties, small drug loading, short action time, low bioavailability, inconvenient application and taking along, and so on, limited its clinical generalization. In order to promote the prescription quality stability, enhance the ability of drug's skin penetration, enhance the curative effect and patient compliance, systematic research was made on Shi-zhen prescription, on the basis of former studies.
In this paper, firstly, the optimal extraction and purification processes were determined by the research on extraction and purification of Shi-zhen prescription. Secondly, the physicochemical properties of the purified materials were mastered by the preformulation studies, thirdly, with integrated application of microemulsion and gel's advantage, the purified materials were made into "Shi-Zhen compound microemulsion-based gels", finally, physicochemical and biology evaluation of the new preparation was made.The main content of the research in this paper was as follows.
1Determination of the extraction and purification processes of Shi-zhen prescription
For the preparation of microemulsion-based gels, with the pharmacodynamics methodology, taking the inhibition rate of mice ears-swelling as the investigation factor, studies on the different influence on prescription's efficacy by decocting separately and together.The result showed as follows:Both single-decoction and mixed-decoction group had a significant effect on inhibiting mice ears-swell ing (P<0.01), compared with the model group, with no significant difference between single-decoction and mixed-decoction group (P>0.05). The result showed that the Shi-zhen prescription could be decocted Separately.the preparation could be made of the purified material and borneol.Taking the inhibition ratio of mice ears-swelling during the mice contact eczema test as the investigation index,studies on the coptidis rhizomas'、sophora flavescens'and paeonia suffruticosa's different extracted and purified materials's effection on the prescription's efficacy by orthogonal experimental design.The result showed that the combination of the purified matetials of total alkaloids from coptidis rhizome, total alkaloids from sophora flavescens, paeonol and borneol had the strongest efficacy. The extraction and purification processes were determined preliminarily. The above findings laid the foundation for the subsequent studies on formulation and processes.
2Optimization of the extraction and purification processes
(1) Determination of ingredient index's content:Studies on content' determination of HLJ(berberine hydrochloride, palmatine, coptisine and epiberberine), K(matrine and oxymatrine)and paeonol, which respectively stand for ingredient index of the purified materials:total alkaloids from coptidis rhizome, total alkaloids from sophora flavescens and crystals from moutan cortex. The established methods for content's determination were sensitive, accurate, simple and practical.(2) Optimization of coptidis rhizome-extraction and purification processes.Taking transfer rate of HLJ as evaluation index,the optimized extraction processes of coptidis rhizome were screened by single factor and orthogonal experimental design. The optimum condition of extraction processes were that the tablets ready for decoction were decocted with8-fold1.5%(m/m) sulfuric acid solution for3times,40min each time. The transfer rate of HLJ was above to93%;Total alkaloids was made from extract by methords of acid-base replacement and salting out method. The yield of total alkaloids was about7.70%, and the content of HLJ was more than80%. The processes of preparation were stability and feasible.(3) Optimization of sophora flavescens-extraction and purification processes:Taking transfer rate of K as evaluation index, the optimized extraction processes of sophora flavescens were screened by single factor and central composite design-response surface experimental design. The optimum condition of extraction processes were that the tablets ready for decoction were decocted with11-fold65%alcohol for2times,65min each time. The transfer rate of K was more than90%. The yield of dried extractum was more than23%. The total alkaloids was purified by732cationic resin processes,the content of which was over41%(based on the calculation of K),and the yield of which was about4.67%. The processes of preparation were stability and feasible.(4) Optimization of paeonia suffruticosa-extraction and purification processes: Taking yield of paeonol as evaluation index, The paeonol was extracted from paeonia suffruticosa by steam distillation technology, and the optimal extraction processes were as follows:the tablets ready for decoction were socked for2h, then decocted with8-fold water.5times crude drug-amuout of distillate was collected. the distillate was placed in refrigerator (4℃) for12h, Filtered, and paeonol was gotten, The yield of paeonol was aboutl.11%, and the content of paeonol was about96%。 The processes of preparation were stability and feasible.
3Preformulation studies
The studies on physicochemical properties of the purified matetials of total alkaloids from coptidis rhizome, total alkaloids from sophora flavescens and paeonol showed that HLJ was slightly soluble in water, k was hydrophilic, their oil and water distribution coefficient were both less than1, and k had larger distribution coefficient. In addition, the paenol was soluble in organic solvents, its oil and water distribution coefficient was larger than the former. Stability test results showed that the total alkaloids from coptidis rhizome and the total alkaloids from sophora flavescens were kept unchanged in the condition of light, wet, and heat, but the paenol was easily volatile. We took HLJ and paenol as the index to explore the purified materials' skin permeation. The result showed that the speed of HLJ's skin permeation was6.36ug·cm-2·h-1and the speed of paenol's skin permeation was6.83ug·cm-2·h-1. Their absorption mechanisms belonged to the zero-order kinetics. All of the above provided the basis for the forms of the choice and the determination of the preparation technology.
4Preparation of Shi-zhen compound microemulsion-based gels
In order to improve drug' ability of skin permeation, microemulsion was used as the drug delivery system.Shi-zhen compound microemulsion-based gels was prepared, combined with the characteristics of microemulsion and gels.In the research of Shi-zhen compound microemulsion-based gels' spreparation, types of oil phase, surfactant, cosurfactant were choosed by single factor and orthogonal experimental design. According to the result, isopropyl myristate (IPM, oil phase), Cremephor EL(EL, surfactant) and glycerol (cosurfactant), and double-distilled water were determined as the composition of the Shi-zhen microemulsion. Percentage composition of microemulsion's each phase was determined by in vitro transdermal permeation experiment. According to the result of the experiment,6.5%isopropyl myristate(IPM),35%double-distilled water and58.5%Cremephor EL/glycerol(1:1) as the optimal prescription of microemulsion was ascertained. The result showed the optimal microemulsion had the best ability of skin permeation.
Studies on physicochemical properties, solubilization and stability of blank micromulsion were investigated primitively. It showed that the microemulsion preparation can increase the purified materials' solubility and the stability to the purified materials, pH, and temperature in the test. Taking the glossiness, viscosity, degree of homogeneity, stretchability of the preparation as the investigation index, carbomer940was chosed as the optimal gels' base material, and the content of it was0.5%. microemulsion-based gels' zetea potential got higher than blank microemulsion, and The new preparation microemulsion-based gels got more stable than blank microemulsion,with diameter less than100nm, showing round shape in the horizon of transmission electron microscope(TEM). Verifying test showed that the processes of preparation for Shi-zhen compound microemulsion-based gels were stability, reasonable and feasible.
5Quality evaluation of the Shi-zhen compound microemulsion-based gels
Biological evaluation:Drug loading of Shi-zhen compound microemulsion-based gels was determered by the dose-effect relationship experiment, which was0.90%(calculated by the amount of the purified materials, the content of HLJ was0.47%). With the same drug loading, Shi-zhen compound microemulsion-based gels'drug efficacy was improved significantly, compared with the original lotion preparation. The Shi-zhen compound microemulsion-based gels had no side effects of irritation, irritability or acute toxicity to the guinea pigs and New Zealand rabbits.
Physicochemical evaluation:Methods of qualitative identification (TLC),and quantitative analysis(HPLC) for microemulsion-based gels were established, which were accurate, stable and reliable. According to the in vitro transdermal permeation experiment, it showed that the component HLJ's skin penetration was improved about16times, and paeonol's was improved about10times than the original lotion preparation. Preliminary stability test showed that Shi-zhen compound microemulsion-based gels had good stability.
Drugs in the Shi-zhen compound microemulsion-based gels had a higher ability of skin permeation and stronger drug efficacy.compared with the orginal lotion, the Shi-zhen compound microemulsion-based gels performed controllable, homogeneous and stable quality, convenient application and good market prospect.
引文
[1]刘捷,叶涛,李义民,等.婴儿湿疹发病因素流行病学调查[J].中国妇幼保健,2008,23(21)：3025-3026.
[2]何玉华,康静,刘光珍,等.太原市479名婴幼儿湿疹发病率及相关因素调查[J].中国中医药信息杂志,2006,13(8)：12-13.
[3]孙景卫,吴孟东.婴幼儿湿疹的药物治疗[J].中国药师,2005,8(4)278-280.
[4]赵辩.临床皮肤病学[M].南京：江苏科学技术出版社,2001：604-606.
[5]樊艺婕,李彤辉,吴茵,等.中药经皮给药的研究[J].陕西中医,2012,33(1)：90-92.
[6]Wang X, Xue M, Gu J, et al. Transdermal microemulsion drug delivery system for impairing male reproductive toxicity and enhancing efficacy of Tripterygium Wilfordii Hook f. [J]. Fitoterapia,2012.
[7]Attivi D, Ajana I, Astier A, et al. Development of microemulsion of mitotane for improvement of oral bioavailability. [J]. Drug Dev Ind Pharm, 2010,36(4):421-427.
[8]Sintov A C, Shapiro L. New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. [J]. J Control Release,2004,95(2):173-183.
[9]王晶,郭俊生,王晓黎.微乳系统在透皮给药中的应用[J].中国医药工业杂志,2007,38(10)：739-742.
[10]齐潇潇,林华庆.现代中药凝胶剂的发展概况[J].国际医药卫生导报,2008,14(6)：110-113.
[11]潘莹,江海燕.浅析中药提取液质量的影响因素[J].时珍国医国药,2002(9)：529-530.
[12]庄延双,蔡皓,刘晓,等.影响中药煎剂质量的因素分析[J].中国药房,2012(11)：1048-1050.
[13]董荣富.中药质量标准目前存在的某些问题[J].中国民族民间医药,2010(20)：21-22.
[14]高新军.推进中药饮片质量标准化进程南京举办中药饮片质量标准国际论坛[J].中医药管理杂志,2008(10)：785.
[15]张钦德,沈伟.中药质量控制标准与中药指纹图谱[Z].中国北京：2008196-200.
[16]魏瑞雪,仇兆丰.影响中药提取质量的主要因素[J].中国现代药物应用, 2009(2)：198.
[17]侯团章,曾建国.中药提取物质量规范化初探[J].世界科学技术,2000(1)：32-34.
[18]崔景朝,赵自明.中药配方颗粒研究进展(Ⅱ)——中药单煎与合煎对比研究概况[J].中国实验方剂学杂志,2011(4)：240-245.
[19]邓轶渊,高文远,陈海霞,等.中药复方合煎与分煎的差异性研究进展[J].中草药,2005(12)：1909-1911.
[20]谢崇义,李国忠,夏明堂,等.中药提取液纯化精制新技术研究进展[J].安徽医药,2008(12)：1225-1227.
[21]姚新生.中药质量标准与中药活性成分研究[Z].中国广东广州：20103-8.
[22]郭学锋.膜分离技术在药物分离纯化中的应用[J].药学与临床研究,2007(2)：96-99.
[23]韩永萍,林强,何绪文.膜分离技术在传统中药生产中的应用[J].时珍国医国药,2009(8)：1983-1985.
[24]李平华,赵汉臣,闫荟.膜分离技术在中药研究开发中的应用[J].中国药房,2007(24)：1918-1920.
[25]李伟,李茜,王媛.大孔树脂在中药黄酮及皂甙类成分分离纯化中的应用[J].新疆中医药,2010(5)：87-89.
[26]白金刚,张典瑞,刘向荣.大孔树脂吸附法在中药分离、纯化中的应用[J].内蒙古中医药,2009(2)：89-90.
[27]张旭,王锦玉,仝燕,等.大孔树脂技术在中药提取纯化中的应用及展望[J].中国实验方剂学杂志,2012(6)：286-290.
[28]Navratil J D. Application of mixture design to optimize cementation of simu-lated spent radioactive ion exchange resins[J]. Nuclear Science and Techniques,2005(3):160-166.
[29]李伟男,南洋,杨德强,等.离子交换树脂在中药制剂中的应用[J].中医药学报,2011(3)：101-102.
[30]何炳林,钱庭宝,彭长久,等.离子交换树脂的制备及其性能测定——Ⅵ.高强度多孔性聚苯乙烯-二乙烯基苯型弱碱性阴离子交换树脂[J].高分子通讯,1965(3)：185-192.
[31]金良,白鸽,崔翰明.黄连总生物碱与离子交换树脂的交换动力学和热力学研究[J].中国新药杂志,2010(23)：2192-2196.
[32]陈飞,鄢可书,李继忠,等.离子交换树脂与黄连提取物制备盐酸小檗碱树脂复合物的研究[J].中国新药杂志,2008(6)：502-505.
[33]国家药典委员会.中华人民共和国药典[M].中国医药科技出版社,2010.
[34]李彩虹,周克元.黄连活性成分的作用及机制研究进展[J].时珍国医国药,2010,21(2)：466-468.
[35]丁晓媚,宁玉梅.黄连的药理研究进展[J].国际中医中药杂志,2011,33(2)：184-186.
[36]杨勇,叶小利,李学刚.4种黄连生物碱的抑菌作用[J].时珍国医国药,2007,18(12)：3013-3014.
[37]孙晶,王立艳.苦参药理作用及临床应用综述[J].黑龙江医药,2003,16(6)：526-527.
[38]丁懿,许磊,等.苦参类生物碱的研究概况[J].辽宁药物与临床,2001,4(4)：182-184.
[39]张虹,丁安伟,张丽.中药牡丹皮的研究进展[J].江苏中医药,2007,39(9)：75-77.
[40]巫冠中,杭秉茜.丹皮的抗炎作用[J].中国药科大学学报,1990,21(4)：222-225.
[41]刘春云,武廷章.凤丹丹皮酚抗菌作用的研究[J].生物学杂志,2000,17(3)：23-24.
[42]李逢春,周晓玲.丹皮酚注射液增强免疫功能的实验研究[J].中国中西医结合杂志,1994,14(1)：37-38.
[43]朱作金,蔡福盛.丹皮酚雾化吸入对大鼠免疫功能的影响[J].广西医科大学学报,1994,11(4)：386-387.
[44]王晖,许卫铭.薄荷醇与冰片的促透作用[J].中草药,1997,28(2)：93-94.
[45]牟家琬,孙玉梅.龙脑与异龙脑的体外抗菌作用的研究[J].华西药学杂志,1989,4(1)：20-22.
[46]朱健平,王宗锐.龙脑促进药物经皮渗透作用的研究[J].中国药学杂志,1999,34(2)：104-106.
[47]郑俊民.经皮给药新剂型[M].北京：人民卫生出版社,2006：589.
[48]Aqil M, Zafar S, Ali A, et al. Transdermal drug delivery of labetolol hydrochloride:system development, in vitro; ex vivo and in vivo characterization. [J]. Curr Drug Deliv,2005,2(2):125-131.
[49]Morimoto K. Transdremal preparations containing dihydro etorphine[J]. CA,1992,129:180.
[50]李涛,李梦晖.微乳化技术及应用分析[J].经济技术协作信息,2009：149.
[51]俞媛,高申,陈琰,等.盐酸哌甲酯-卵磷脂微乳的制备及其透皮吸收作用[J].中国药学杂志,2005,40(11)：843-845.
[52]Rhee Ys C J. Transdermal delivery of ketoprofen using microemulsions[J]. Int J Pharm,200l,228(1-2):161-170.
[53]管咏梅.雷公藤微乳凝胶经皮给药系统的设计与评价[D].成都：成都中医药大学,2008.
[54]钟华,尹蓉莉,谢秀琼,等.莪术微乳凝胶的成型工艺研究[J].华西药学杂志,2010：
[55]刘继勇,韩盈,杨明,等.丹皮酚微乳凝胶剂的制备及体外透皮特性研究[J].中国中药杂志,2009,34(21)：2730-2733.
[56]严永清,朱丹妮,余伯阳,等.中药复方系统研究的思路与实践[J].中国天然药物,2006,4(5)：322-326.
[57]匡艳辉,朱晶晶,王智民,等.一测多评法测定黄连中小檗碱、巴马汀、黄连碱、表小檗碱、药根碱含量[J].中国药学杂志,2009：390-394.
[58]匡艳辉,朱晶晶,王智民,等.黄连属药用植物化学成分和质量控制的研究进展[J].中国药学杂志,2008,43(15)：1121-1125.
[59]汪坤,张振凌,贾秀梅.一测多评法优选黄连最佳提取工艺[J].中国实验方剂学杂志,2011,17(24)：9-11.
[60]赵兴红,王光辉,刘国安,等.高效液相色谱技术(HPLC)在中药研究中的应用[J].中华临床医学卫生杂志,2006,4(1)：34-36.
[61]张红伟,张振凌.“一测多评”法在中药质量控制中的研究进展[J].海峡药学,2010,22(11)：88-89.
[62]潘广洲,李峰,李键.苦参碱和氧化苦参碱的转化对苦参提取工艺的影响[J].现代中药研究与实践,2008,22(2)：52-54.
[63]王道武,庞雪,肖文,等.正交实验法优化黄连中小檗碱盐析提取工艺[J].化学与生物工程,2010,27(12)：45-48.
[64]席国萍,宋国斌.黄连中小檗碱提取方法研究进展[J].贵州农业科学,2009,37(1)：8-10.
[65]许沛虎,高媛,张雪琼,等.黄连总生物碱纯化工艺研究[J].时珍国医国药,2007,18(12)：3079-3080.
[66]王道武,庞雪,肖文,等.正交实验法优化黄连中小檗碱盐析提取工艺[J].化学与生物工程,2010,27(12)：45-48.
[67]仝燕,王锦玉,张锴镔,等.苦参总生物碱提取纯化工艺研究[J].中国实验方剂学杂志,2007,13(1)：19-22.
[68]敖道夫,巴达拉胡,布日额.正交实验法优选苦参总碱提取工艺[J].内蒙古民族大学学报：自然科学版,2009,24(1)：75-78.
[69]刘逆夫,李瑞明.阳离子树脂纯化苦参生物碱的工艺研究[J].中国中医药现代远程教育,2006,4(12)：22-24.
[70]代龙.阳离子交换树脂酸水洗脱法纯化苦参总碱的工艺优选[J].齐鲁药事,2008,27(10)：621-623.
[71]代龙.阳离子交换树脂法不同洗脱剂纯化苦参总碱的工艺研究[J].现代中药研究与实践,2009,23(3)：45-47.
[72]段晓颖,高卫芳,周淑娟,等.牡丹皮中丹皮酚的提取工艺研究[J].中国实验方剂学杂志,2009：41-42.
[73]曹刚,钦传光,尚晓娅.丹皮酚的提取及分析方法研究进展[J].中国药业,2009,18(18)：25-27.
[74]田宝成,贾昌平,杨军涛,等Box-Behnken效应面法优化红旱莲总黄酮提取工艺的研究[J].中成药,2010,32(3)：389-392.
[75]吴伟,崔光华.星点设计—效应面优化法及其在药学中的应用[J].国外医学：药学分册,2000,27(5)：292-298.
[76]邱颖,朱玲,孙晓英.星点设计-效应面优化法与正交设计和均匀设计的比较及其在药剂研究中的应用[J].海峡药学,2011,23(2)：18-20.
[77]汤丽娟,魏树礼.处方前研究的意义及方法[J].中国医药工业杂志,1989,20(3)：133-134.
[78]邓卫东,王琳,李国锋.氢化可的松油水分配系数及其皮肤渗透速率的相关性研究[J].佛山科学技术学院学报：自然科学版,2011,29(3)：68-71.
[79]钟伟,王鹏.HPLC法测定离体透皮接受液中丹参酮Ⅱ A的浓度[J].中草药,1999,30(2)：96-97.
[80]王英姿,任天池,孙秀梅.高乌甲素的油水分配系数及透皮吸收速率常数的相关性研究[J].山东中医药大学学报,2006,30(2)：155-156.
[81]梁文权,林武.药物分子体积和油水分配系数与经皮吸收的关系[J].药学学报,1992,27(9)：684-689.
[82]Liu D, Feng J F. [Determination of apparent aqueous solubility and apparent oil-water partition coefficients of three bufadienolides composition]. [J]. Zhongguo Zhong Yao Za Zhi,2008,33(11):1256-1258.
[83]Standal S H, Blokhus A M, Haavik J, et al. Partition Coefficients and Interfacial Activity for Polar Components in Oil/Water Model Systems.[J]. J Colloid Interface Sci,1999,212(1):33-41.
[84]Anderson C, Andersson T, Molander M. Ethanol absorption across human skin measured by in vivo microdialysis technique. [J]. Acta Derm Venereol, 1991,71(5):389-393.
[85]Groth L. Cutaneous microdialysis. A new technique for the assessment of skin penetration. [J]. Curr Probl Dermatol,1998,26:90-98.
[86]Morgan C J, Renwick A G, Friedmann P S. The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. [J]. Br J Dermatol, 2003,148(3):434-443.
[87]Benfeldt E, Serup J, Menne T. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin:in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. [J]. Br J Dermatol,1999,140(4):739-748.
[88]Hegemann L, Forstinger C, Partsch B, et al. Microdialysis in cutaneous pharmacology:kinetic analysis of transdermally delivered nicotine. [J]. J Invest Dermatol,1995,104(5):839-843.
[89]Boelsma E, Anderson C, Karlsson A M, et al. Microdialysis technique as a method to study the percutaneous penetration of methyl nicotinate through excised human skin, reconstructed epidermis, and human skin in vivo. [J]. Pharm Res,2000,17(2):141-147.
[90]Stagni G,O'Donnell D, Liu Y J, et al. Intradermal microdialysis: kinetics of iontophoretically delivered propranolol in forearm dermis. [J]. J Control Release,2000,63(3):331-339.
[91]Ault J M, Lunte C E, Meltzer N M, et al. Microdialysis sampling for the investigation of dermal drug transport. [J]. Pharm Res,1992,9(10): 1256-1261.
[92]Ault J M, Riley C M, Meltzer N M, et al. Dermal microdialysis sampling in vivo. [J]. Pharm Res,1994,11(11):1631-1639.
[93]Matsuyama K, Nakashima M, Ichikawa M, et al. In vivo microdialysis for the transdermal absorption of valproate in rats. [J]. Biol Pharm Bull, 1994,17(10):1395-1398.
[94]Nakashima M, Takeuchi N, Hamada M, et al. In vivo microdialysis for pharmacokinetic investigations:a plasma protein binding study of valproate in rabbits.[J]. Biol Pharm Bull,1994,17(12):1630-1634.
[95]Nakashima M, Zhao M F, Nakashima M N, et al. In vivo microdialysis to determine the relative pharmacokinetics of drugs. [J]. Biol Pharm Bull, 1996,19(7):988-994.
[96]Muller M, Mascher H, Kikuta C, et al. Diclofenac concentrations in defined tissue layers after topical administration. [J]. Clin Pharmacol Ther,1997,62(3):293-299.
[97]黄桂红,杨柳青.川芎嗪微乳凝胶的制备及体外释放度的研究[J].中国医药指南,2012,10(3)：229-231.
[98]闫圣坤,张连富.番茄红素微乳化体系的制备[J].食品工业科技,2012：322-325.
[99]高鹏飞.经皮渗透促进剂的研究[J].广州化工,2010：42-43.
[100]陈智,李兆明,田景振.微乳制剂处方选择研究概况[J].食品与药品,2009,11(4)：61-63.
[101]金方.胰岛素口服自微乳给药系统的研究[D].上海：上海医药工业研究院,2004.
[102]谢敏,邢建国,王新春,等.天山雪莲透皮微乳制备处方优化[J].中国实验方剂学杂志,2012,18(1)：8-11.
[103]易红,杨华,高进,等.0/w型微乳凝胶粒度分布特性的研究[J].中国实验方剂学杂志,2011,17(17)：1-4.
[104]华海婴,杨婷,赵永星.乙酰氧基胡椒酚乙酸酯亚微乳的制备及其性质考察[J].中草药,2011,42(12)：2424-2429.
[105]王文清,顾国兴.电导法研究水/十二烷基苯磺酸钠/正戊醇/正庚烷体系反向胶束和W/O型微…[J].铀矿冶,1997,16(4)：252-258.
[106]易涛.固体自微乳化给药系统的研究[D].武汉：华中科技大学,2008.
[107]潘国梁,贾晓斌,魏惠华,等.药用微乳伪三元相图的几种制备方法比较研究[J].中国药房,2006,17(1)：21-23.
[108]郭宏.奥沙普秦透皮给药系统的设计与评价[D].沈阳：沈阳药科大学,2007.
[109]高振砷,王兰,王建夺.姜黄素体外经皮渗透性[J].中国实验方剂学杂志,2012,18(2)：39-41.
[110]徐小燕,邱碧菡,潘林梅.微乳透皮给药载体的制备及透皮影响因素研究进展[J].中国药房,2011,22(37)：3528-3530.
[111]张晓乐,赵蕊.卡波姆基质口腔溃疡乳化型凝胶的研制[J].中国药学杂志,1995,30(7)：417-418.
[112]傅崇东,徐惠南.卡波姆在药剂中的应用研究进展[J].国外医药：合成药.生化药.制剂分册,1999,20(2)：121-125.
[113]李成蓉,黄筱萍.卡波姆的性质和应用[J].华西药学杂志,1999,14(2)：119.
[114]于淼,焦拥政,仝小林,等.中药复方实验研究量效关系的进展与思考[J].中医杂志,2011,52(17)：1517-1520.
[115]孟丽,崔芳,龚淼,等.透射电镜电子染色方法的改良[J].电子显微学报,2010,29(2)：189-190.
[2]何玉华,康静,刘光珍,等.太原市479名婴幼儿湿疹发病率及相关因素调查[J].中国中医药信息杂志,2006,13(8)：12-13.
[3]孙景卫,吴孟东.婴幼儿湿疹的药物治疗[J].中国药师,2005,8(4)278-280.
[4]赵辩.临床皮肤病学[M].南京：江苏科学技术出版社,2001：604-606.
[5]樊艺婕,李彤辉,吴茵,等.中药经皮给药的研究[J].陕西中医,2012,33(1)：90-92.
[6]Wang X, Xue M, Gu J, et al. Transdermal microemulsion drug delivery system for impairing male reproductive toxicity and enhancing efficacy of Tripterygium Wilfordii Hook f. [J]. Fitoterapia,2012.
[7]Attivi D, Ajana I, Astier A, et al. Development of microemulsion of mitotane for improvement of oral bioavailability. [J]. Drug Dev Ind Pharm, 2010,36(4):421-427.
[8]Sintov A C, Shapiro L. New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. [J]. J Control Release,2004,95(2):173-183.
[9]王晶,郭俊生,王晓黎.微乳系统在透皮给药中的应用[J].中国医药工业杂志,2007,38(10)：739-742.
[10]齐潇潇,林华庆.现代中药凝胶剂的发展概况[J].国际医药卫生导报,2008,14(6)：110-113.
[11]潘莹,江海燕.浅析中药提取液质量的影响因素[J].时珍国医国药,2002(9)：529-530.
[12]庄延双,蔡皓,刘晓,等.影响中药煎剂质量的因素分析[J].中国药房,2012(11)：1048-1050.
[13]董荣富.中药质量标准目前存在的某些问题[J].中国民族民间医药,2010(20)：21-22.
[14]高新军.推进中药饮片质量标准化进程南京举办中药饮片质量标准国际论坛[J].中医药管理杂志,2008(10)：785.
[15]张钦德,沈伟.中药质量控制标准与中药指纹图谱[Z].中国北京：2008196-200.
[16]魏瑞雪,仇兆丰.影响中药提取质量的主要因素[J].中国现代药物应用, 2009(2)：198.
[17]侯团章,曾建国.中药提取物质量规范化初探[J].世界科学技术,2000(1)：32-34.
[18]崔景朝,赵自明.中药配方颗粒研究进展(Ⅱ)——中药单煎与合煎对比研究概况[J].中国实验方剂学杂志,2011(4)：240-245.
[19]邓轶渊,高文远,陈海霞,等.中药复方合煎与分煎的差异性研究进展[J].中草药,2005(12)：1909-1911.
[20]谢崇义,李国忠,夏明堂,等.中药提取液纯化精制新技术研究进展[J].安徽医药,2008(12)：1225-1227.
[21]姚新生.中药质量标准与中药活性成分研究[Z].中国广东广州：20103-8.
[22]郭学锋.膜分离技术在药物分离纯化中的应用[J].药学与临床研究,2007(2)：96-99.
[23]韩永萍,林强,何绪文.膜分离技术在传统中药生产中的应用[J].时珍国医国药,2009(8)：1983-1985.
[24]李平华,赵汉臣,闫荟.膜分离技术在中药研究开发中的应用[J].中国药房,2007(24)：1918-1920.
[25]李伟,李茜,王媛.大孔树脂在中药黄酮及皂甙类成分分离纯化中的应用[J].新疆中医药,2010(5)：87-89.
[26]白金刚,张典瑞,刘向荣.大孔树脂吸附法在中药分离、纯化中的应用[J].内蒙古中医药,2009(2)：89-90.
[27]张旭,王锦玉,仝燕,等.大孔树脂技术在中药提取纯化中的应用及展望[J].中国实验方剂学杂志,2012(6)：286-290.
[28]Navratil J D. Application of mixture design to optimize cementation of simu-lated spent radioactive ion exchange resins[J]. Nuclear Science and Techniques,2005(3):160-166.
[29]李伟男,南洋,杨德强,等.离子交换树脂在中药制剂中的应用[J].中医药学报,2011(3)：101-102.
[30]何炳林,钱庭宝,彭长久,等.离子交换树脂的制备及其性能测定——Ⅵ.高强度多孔性聚苯乙烯-二乙烯基苯型弱碱性阴离子交换树脂[J].高分子通讯,1965(3)：185-192.
[31]金良,白鸽,崔翰明.黄连总生物碱与离子交换树脂的交换动力学和热力学研究[J].中国新药杂志,2010(23)：2192-2196.
[32]陈飞,鄢可书,李继忠,等.离子交换树脂与黄连提取物制备盐酸小檗碱树脂复合物的研究[J].中国新药杂志,2008(6)：502-505.
[33]国家药典委员会.中华人民共和国药典[M].中国医药科技出版社,2010.
[34]李彩虹,周克元.黄连活性成分的作用及机制研究进展[J].时珍国医国药,2010,21(2)：466-468.
[35]丁晓媚,宁玉梅.黄连的药理研究进展[J].国际中医中药杂志,2011,33(2)：184-186.
[36]杨勇,叶小利,李学刚.4种黄连生物碱的抑菌作用[J].时珍国医国药,2007,18(12)：3013-3014.
[37]孙晶,王立艳.苦参药理作用及临床应用综述[J].黑龙江医药,2003,16(6)：526-527.
[38]丁懿,许磊,等.苦参类生物碱的研究概况[J].辽宁药物与临床,2001,4(4)：182-184.
[39]张虹,丁安伟,张丽.中药牡丹皮的研究进展[J].江苏中医药,2007,39(9)：75-77.
[40]巫冠中,杭秉茜.丹皮的抗炎作用[J].中国药科大学学报,1990,21(4)：222-225.
[41]刘春云,武廷章.凤丹丹皮酚抗菌作用的研究[J].生物学杂志,2000,17(3)：23-24.
[42]李逢春,周晓玲.丹皮酚注射液增强免疫功能的实验研究[J].中国中西医结合杂志,1994,14(1)：37-38.
[43]朱作金,蔡福盛.丹皮酚雾化吸入对大鼠免疫功能的影响[J].广西医科大学学报,1994,11(4)：386-387.
[44]王晖,许卫铭.薄荷醇与冰片的促透作用[J].中草药,1997,28(2)：93-94.
[45]牟家琬,孙玉梅.龙脑与异龙脑的体外抗菌作用的研究[J].华西药学杂志,1989,4(1)：20-22.
[46]朱健平,王宗锐.龙脑促进药物经皮渗透作用的研究[J].中国药学杂志,1999,34(2)：104-106.
[47]郑俊民.经皮给药新剂型[M].北京：人民卫生出版社,2006：589.
[48]Aqil M, Zafar S, Ali A, et al. Transdermal drug delivery of labetolol hydrochloride:system development, in vitro; ex vivo and in vivo characterization. [J]. Curr Drug Deliv,2005,2(2):125-131.
[49]Morimoto K. Transdremal preparations containing dihydro etorphine[J]. CA,1992,129:180.
[50]李涛,李梦晖.微乳化技术及应用分析[J].经济技术协作信息,2009：149.
[51]俞媛,高申,陈琰,等.盐酸哌甲酯-卵磷脂微乳的制备及其透皮吸收作用[J].中国药学杂志,2005,40(11)：843-845.
[52]Rhee Ys C J. Transdermal delivery of ketoprofen using microemulsions[J]. Int J Pharm,200l,228(1-2):161-170.
[53]管咏梅.雷公藤微乳凝胶经皮给药系统的设计与评价[D].成都：成都中医药大学,2008.
[54]钟华,尹蓉莉,谢秀琼,等.莪术微乳凝胶的成型工艺研究[J].华西药学杂志,2010：
[55]刘继勇,韩盈,杨明,等.丹皮酚微乳凝胶剂的制备及体外透皮特性研究[J].中国中药杂志,2009,34(21)：2730-2733.
[56]严永清,朱丹妮,余伯阳,等.中药复方系统研究的思路与实践[J].中国天然药物,2006,4(5)：322-326.
[57]匡艳辉,朱晶晶,王智民,等.一测多评法测定黄连中小檗碱、巴马汀、黄连碱、表小檗碱、药根碱含量[J].中国药学杂志,2009：390-394.
[58]匡艳辉,朱晶晶,王智民,等.黄连属药用植物化学成分和质量控制的研究进展[J].中国药学杂志,2008,43(15)：1121-1125.
[59]汪坤,张振凌,贾秀梅.一测多评法优选黄连最佳提取工艺[J].中国实验方剂学杂志,2011,17(24)：9-11.
[60]赵兴红,王光辉,刘国安,等.高效液相色谱技术(HPLC)在中药研究中的应用[J].中华临床医学卫生杂志,2006,4(1)：34-36.
[61]张红伟,张振凌.“一测多评”法在中药质量控制中的研究进展[J].海峡药学,2010,22(11)：88-89.
[62]潘广洲,李峰,李键.苦参碱和氧化苦参碱的转化对苦参提取工艺的影响[J].现代中药研究与实践,2008,22(2)：52-54.
[63]王道武,庞雪,肖文,等.正交实验法优化黄连中小檗碱盐析提取工艺[J].化学与生物工程,2010,27(12)：45-48.
[64]席国萍,宋国斌.黄连中小檗碱提取方法研究进展[J].贵州农业科学,2009,37(1)：8-10.
[65]许沛虎,高媛,张雪琼,等.黄连总生物碱纯化工艺研究[J].时珍国医国药,2007,18(12)：3079-3080.
[66]王道武,庞雪,肖文,等.正交实验法优化黄连中小檗碱盐析提取工艺[J].化学与生物工程,2010,27(12)：45-48.
[67]仝燕,王锦玉,张锴镔,等.苦参总生物碱提取纯化工艺研究[J].中国实验方剂学杂志,2007,13(1)：19-22.
[68]敖道夫,巴达拉胡,布日额.正交实验法优选苦参总碱提取工艺[J].内蒙古民族大学学报：自然科学版,2009,24(1)：75-78.
[69]刘逆夫,李瑞明.阳离子树脂纯化苦参生物碱的工艺研究[J].中国中医药现代远程教育,2006,4(12)：22-24.
[70]代龙.阳离子交换树脂酸水洗脱法纯化苦参总碱的工艺优选[J].齐鲁药事,2008,27(10)：621-623.
[71]代龙.阳离子交换树脂法不同洗脱剂纯化苦参总碱的工艺研究[J].现代中药研究与实践,2009,23(3)：45-47.
[72]段晓颖,高卫芳,周淑娟,等.牡丹皮中丹皮酚的提取工艺研究[J].中国实验方剂学杂志,2009：41-42.
[73]曹刚,钦传光,尚晓娅.丹皮酚的提取及分析方法研究进展[J].中国药业,2009,18(18)：25-27.
[74]田宝成,贾昌平,杨军涛,等Box-Behnken效应面法优化红旱莲总黄酮提取工艺的研究[J].中成药,2010,32(3)：389-392.
[75]吴伟,崔光华.星点设计—效应面优化法及其在药学中的应用[J].国外医学：药学分册,2000,27(5)：292-298.
[76]邱颖,朱玲,孙晓英.星点设计-效应面优化法与正交设计和均匀设计的比较及其在药剂研究中的应用[J].海峡药学,2011,23(2)：18-20.
[77]汤丽娟,魏树礼.处方前研究的意义及方法[J].中国医药工业杂志,1989,20(3)：133-134.
[78]邓卫东,王琳,李国锋.氢化可的松油水分配系数及其皮肤渗透速率的相关性研究[J].佛山科学技术学院学报：自然科学版,2011,29(3)：68-71.
[79]钟伟,王鹏.HPLC法测定离体透皮接受液中丹参酮Ⅱ A的浓度[J].中草药,1999,30(2)：96-97.
[80]王英姿,任天池,孙秀梅.高乌甲素的油水分配系数及透皮吸收速率常数的相关性研究[J].山东中医药大学学报,2006,30(2)：155-156.
[81]梁文权,林武.药物分子体积和油水分配系数与经皮吸收的关系[J].药学学报,1992,27(9)：684-689.
[82]Liu D, Feng J F. [Determination of apparent aqueous solubility and apparent oil-water partition coefficients of three bufadienolides composition]. [J]. Zhongguo Zhong Yao Za Zhi,2008,33(11):1256-1258.
[83]Standal S H, Blokhus A M, Haavik J, et al. Partition Coefficients and Interfacial Activity for Polar Components in Oil/Water Model Systems.[J]. J Colloid Interface Sci,1999,212(1):33-41.
[84]Anderson C, Andersson T, Molander M. Ethanol absorption across human skin measured by in vivo microdialysis technique. [J]. Acta Derm Venereol, 1991,71(5):389-393.
[85]Groth L. Cutaneous microdialysis. A new technique for the assessment of skin penetration. [J]. Curr Probl Dermatol,1998,26:90-98.
[86]Morgan C J, Renwick A G, Friedmann P S. The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. [J]. Br J Dermatol, 2003,148(3):434-443.
[87]Benfeldt E, Serup J, Menne T. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin:in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. [J]. Br J Dermatol,1999,140(4):739-748.
[88]Hegemann L, Forstinger C, Partsch B, et al. Microdialysis in cutaneous pharmacology:kinetic analysis of transdermally delivered nicotine. [J]. J Invest Dermatol,1995,104(5):839-843.
[89]Boelsma E, Anderson C, Karlsson A M, et al. Microdialysis technique as a method to study the percutaneous penetration of methyl nicotinate through excised human skin, reconstructed epidermis, and human skin in vivo. [J]. Pharm Res,2000,17(2):141-147.
[90]Stagni G,O'Donnell D, Liu Y J, et al. Intradermal microdialysis: kinetics of iontophoretically delivered propranolol in forearm dermis. [J]. J Control Release,2000,63(3):331-339.
[91]Ault J M, Lunte C E, Meltzer N M, et al. Microdialysis sampling for the investigation of dermal drug transport. [J]. Pharm Res,1992,9(10): 1256-1261.
[92]Ault J M, Riley C M, Meltzer N M, et al. Dermal microdialysis sampling in vivo. [J]. Pharm Res,1994,11(11):1631-1639.
[93]Matsuyama K, Nakashima M, Ichikawa M, et al. In vivo microdialysis for the transdermal absorption of valproate in rats. [J]. Biol Pharm Bull, 1994,17(10):1395-1398.
[94]Nakashima M, Takeuchi N, Hamada M, et al. In vivo microdialysis for pharmacokinetic investigations:a plasma protein binding study of valproate in rabbits.[J]. Biol Pharm Bull,1994,17(12):1630-1634.
[95]Nakashima M, Zhao M F, Nakashima M N, et al. In vivo microdialysis to determine the relative pharmacokinetics of drugs. [J]. Biol Pharm Bull, 1996,19(7):988-994.
[96]Muller M, Mascher H, Kikuta C, et al. Diclofenac concentrations in defined tissue layers after topical administration. [J]. Clin Pharmacol Ther,1997,62(3):293-299.
[97]黄桂红,杨柳青.川芎嗪微乳凝胶的制备及体外释放度的研究[J].中国医药指南,2012,10(3)：229-231.
[98]闫圣坤,张连富.番茄红素微乳化体系的制备[J].食品工业科技,2012：322-325.
[99]高鹏飞.经皮渗透促进剂的研究[J].广州化工,2010：42-43.
[100]陈智,李兆明,田景振.微乳制剂处方选择研究概况[J].食品与药品,2009,11(4)：61-63.
[101]金方.胰岛素口服自微乳给药系统的研究[D].上海：上海医药工业研究院,2004.
[102]谢敏,邢建国,王新春,等.天山雪莲透皮微乳制备处方优化[J].中国实验方剂学杂志,2012,18(1)：8-11.
[103]易红,杨华,高进,等.0/w型微乳凝胶粒度分布特性的研究[J].中国实验方剂学杂志,2011,17(17)：1-4.
[104]华海婴,杨婷,赵永星.乙酰氧基胡椒酚乙酸酯亚微乳的制备及其性质考察[J].中草药,2011,42(12)：2424-2429.
[105]王文清,顾国兴.电导法研究水/十二烷基苯磺酸钠/正戊醇/正庚烷体系反向胶束和W/O型微…[J].铀矿冶,1997,16(4)：252-258.
[106]易涛.固体自微乳化给药系统的研究[D].武汉：华中科技大学,2008.
[107]潘国梁,贾晓斌,魏惠华,等.药用微乳伪三元相图的几种制备方法比较研究[J].中国药房,2006,17(1)：21-23.
[108]郭宏.奥沙普秦透皮给药系统的设计与评价[D].沈阳：沈阳药科大学,2007.
[109]高振砷,王兰,王建夺.姜黄素体外经皮渗透性[J].中国实验方剂学杂志,2012,18(2)：39-41.
[110]徐小燕,邱碧菡,潘林梅.微乳透皮给药载体的制备及透皮影响因素研究进展[J].中国药房,2011,22(37)：3528-3530.
[111]张晓乐,赵蕊.卡波姆基质口腔溃疡乳化型凝胶的研制[J].中国药学杂志,1995,30(7)：417-418.
[112]傅崇东,徐惠南.卡波姆在药剂中的应用研究进展[J].国外医药：合成药.生化药.制剂分册,1999,20(2)：121-125.
[113]李成蓉,黄筱萍.卡波姆的性质和应用[J].华西药学杂志,1999,14(2)：119.
[114]于淼,焦拥政,仝小林,等.中药复方实验研究量效关系的进展与思考[J].中医杂志,2011,52(17)：1517-1520.
[115]孟丽,崔芳,龚淼,等.透射电镜电子染色方法的改良[J].电子显微学报,2010,29(2)：189-190.